Methotrexate therapy of T-cell large granular lymphocytic leukemia impact of STAT3 mutation - Qiu, Zhi-Yuan; Fan, Lei; Wang, Rong; Gale, Robert Peter; Liang, Hua-Jin; Wang, Man; Wang, Li; Wu, Yu-Jie; Qiao, Chun; Chen, Yao-Yu; Xu, Wei; Qian, Jun; et al. (Oncotarget, 2016)
Keywords: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic - therapeutic use; Antineoplastic Agents, Hormonal - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biomarkers, Tumor - blood; Blood Sedimentation - drug effects; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leukemia, Large Granular Lymphocytic - blood; Leukemia, Large Granular Lymphocytic - drug therapy; Leukemia, Large Granular Lymphocytic - genetics; Leukemia, Large Granular Lymphocytic - mortality; Male; Methotrexate - therapeutic use; Middle Aged; Mutation; Prednisone - therapeutic use; Red-Cell Aplasia, Pure - drug therapy; Red-Cell Aplasia, Pure - etiology; Remission Induction - methods; Research Paper; Sequence Analysis, DNA; STAT3 Transcription Factor - genetics; Time Factors; Treatment Outcome; T-cell large granular lymphocytic leukemia; methotrexate; STAT3